JNJ

AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Fierce Biotech
AstraZeneca
IBD
AbbVie
JNJ
brazikumab
Skyrizi
Stelara
Flag link:
Johnson & Johnson cites rebates and discounts for drug price increases
Johnson & Johnson cites rebates and discounts for drug price increases
Fierce Pharma
JNJ
drug pricing
drug rebates
drug discounts
Flag link:
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
JNJ
Janssen
Tremfya
psoriasis
real world data
Flag link:
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Amgen settles patent lawsuit over biosimilar of J&J's big-selling Stelara
Yahoo/Reuters
JNJ
Amgen
patents
Stelara
biosimilars
legal
Flag link:
J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza
J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza
Fierce Pharma
JNJ
schizophrenia
generics
Trinza
Viatris
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Clinical Trials Arena
JNJ
Janssen
clinical trials
Tremyfa
ulcerative colitis
Flag link:
Does Johnson & Johnson's Kenvue Spinoff Make Sense?
Does Johnson & Johnson's Kenvue Spinoff Make Sense?
Motley Fool
JNJ
consumer health
spinoffs
Kenvue
Flag link:
Judge orders J&J, talc opponents to engage in settlement talks
Judge orders J&J, talc opponents to engage in settlement talks
Fierce Pharma
JNJ
legal
bankruptcy
Flag link:
J&J sets top price for consumer health unit Kenvue’s IPO
J&J sets top price for consumer health unit Kenvue’s IPO
Pharmaphorum
JNJ
spinoff
Kenvue
IPOs
consumer health
Flag link:
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
BioSpace
JNJ
Janssen
Cellular Biomedicine
CAR-T
diffuse large B-cell lymphoma
Flag link:
The FTC put pharma giants on notice for deceptive marketing claims. But does it actually have the authority?
The FTC put pharma giants on notice for deceptive marketing claims. But does it actually have the authority?
Medical Marketing and Media
FTC
pharma marketing
deceptive marketing
JNJ
Pfizer
Flag link:
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
AbbVie
Amgen
Bristol Myers Squibb
Eli Lilly
Gilead Sceinces
JNJ
Merck
Pfizer
Regeneron
patents
activists
Flag link:
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
CNBC
JNJ
consumer health
IPOs
Kenvue
spinoffs
Flag link:
J&J takes on Medtronic and Boston in pulsed field ablation
J&J takes on Medtronic and Boston in pulsed field ablation
EP Vantage
JNJ
Medtech
pulsed field ablation
Medtronic
Boston Scientific
atrial fibrillation
Varipulse
Flag link:
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Benzinga
Genmab
JNJ
Janssen
Darzalex
Flag link:
J&J claims first approval for PARP combo Akeega
J&J claims first approval for PARP combo Akeega
Pharmaphorum
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Flag link:
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Amgen
Regeneron Pharmaceuticals
Sanofi
Supreme Court
patents
Pfizer
Bayer
Roche
Genentech
AstraZeneca
JNJ
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:

Pages